Non-Cystic Fibrosis Bronchiectasis (NCFB): Diagnosis, Treatment, and Management
Uncovering the rising hidden burden Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic respiratory disease characterized by abnormal dilation of the bronchi and bronchioles, leading to recurrent infections and progressive loss of lung function. It is estimated that there are around 200,000 Non-Cystic Fibrosis Bronchiectasis patients in the United States, and the Non-Cystic Fibrosis Bronchiectasis prevalence is increasing worldwide. However, NCFB is often overlooked, and there is a lack of awareness and understanding of the disease among healthcare professionals and the general public. A Call for non-cystic fibrosis bronchiectasis treatment improvement The current standard of care for NCFB includes airway clearance techniques, antibiotics, and bronchodilators. However, there are no approved disease-modifying therapies for NCFB , and the available treatments only provide symptomatic relief and do not address the underlying cause of the disease. NCFB patients are in need of more